The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5,055.00
Bid: 4,326.00
Ask: 5,115.00
Change: 0.00 (0.00%)
Spread: 789.00 (18.239%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5,055.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

9 Jul 2013 07:00

RNS Number : 7239I
Intertek Group PLC
09 July 2013
 



Stock Exchange Release

9 July 2013, 7.00am London, UK

Intertek announces new acquisition extending its Pharmaceutical Services

Intertek Group plc (Intertek), a leading quality solutions provider to industries worldwide, announces that it has acquired Melbourn Scientific Ltd (Melbourn), a specialist pharmaceutical products testing business.

Melbourn is a privately owned UK company based near Cambridge, a heartland of the UK's pharma and biotech industry. It employs over 80 expert scientists and staff and reported £4 million of revenue in 2012.

The company has built a strong reputation over the last 24 years providing expert testing and formulation services to the international pharmaceutical industry, with focus on the testing and evaluation of nasally and orally inhaled drugs and their delivery systems such as inhalers and nebulisers.

This continues to be a fast growing sector of the industry as pharmaceutical and biotechnology companies continue to search for alternative delivery systems for current and next generation drugs.

 

Wolfhart Hauser, Chief Executive Officer of Intertek, commented: 

"We are pleased to welcome this group of highly respected scientists to Intertek which extends the portfolio of capabilities within our Pharmaceutical Services business in the important and growing area of alternative drug delivery methods. By combining our expertise in physical characterisation of medicinal compounds and drug to device interaction with Melbourn's specialist capabilities, we have an unrivalled offering to our clients."

-ends-

Contacts

Aston Swift, Intertek Telephone: +44 (0) 20 7396 3400

aston.swift@intertek.com

 

Richard Mountain, FTI Consulting Telephone: +44 (0) 20 7269 7186

richard.mountain@fticonsulting.com

 

About Intertek

Intertek is a leading quality solutions provider to industries worldwide. From auditing and inspection, to testing, training, advisory, quality assurance and certification, Intertek adds value to customers' products, processes and assets. With a network of more than 1,000 laboratories and offices and over 35,000 people in more than 100 countries, Intertek supports companies' success in a global marketplace. Intertek helps its customers to meet end users' expectations for safety, sustainability, performance, integrity and desirability in virtually any market worldwide. Visit www.intertek.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAAXSEDXDEFF
Date   Source Headline
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement
23rd May 20221:00 pmRNSBlock listing Interim Review
4th Apr 20223:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
18th Mar 20229:00 amRNSAnnual Financial Report
14th Mar 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.